![NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma | British Journal of Cancer NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-023-02534-1/MediaObjects/41416_2023_2534_Fig1_HTML.png)
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma | British Journal of Cancer
Patient disposition. Q2W, once every 2 weeks; RP2D, recommended phase 2... | Download Scientific Diagram
![Clinical Trial: Gallium maltolate (recommended phase 2 dose) for Glioblastoma (NCT04319276) - YouTube Clinical Trial: Gallium maltolate (recommended phase 2 dose) for Glioblastoma (NCT04319276) - YouTube](https://i.ytimg.com/vi/qKe5TiF49Fw/maxresdefault.jpg)
Clinical Trial: Gallium maltolate (recommended phase 2 dose) for Glioblastoma (NCT04319276) - YouTube
![Abbreviations: CR1, first complete remission; RP2D, recommended phase 2... | Download Scientific Diagram Abbreviations: CR1, first complete remission; RP2D, recommended phase 2... | Download Scientific Diagram](https://www.researchgate.net/publication/317276029/figure/fig4/AS:667090289688586@1536058127612/Abbreviations-CR1-first-complete-remission-RP2D-recommended-phase-2-dose-TRM.png)
Abbreviations: CR1, first complete remission; RP2D, recommended phase 2... | Download Scientific Diagram
![533 An open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors | Journal for 533 An open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors | Journal for](https://jitc.bmj.com/content/jitc/9/Suppl_2/A564/F1.large.jpg)
533 An open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors | Journal for
![Trial profile. DLT = doselimiting toxicity; RP2D = recommended phase 2 dose | Download Scientific Diagram Trial profile. DLT = doselimiting toxicity; RP2D = recommended phase 2 dose | Download Scientific Diagram](https://www.researchgate.net/publication/351214028/figure/fig1/AS:1023263790596096@1620976507206/Trial-profile-DLT-doselimiting-toxicity-RP2D-recommended-phase-2-dose.png)
Trial profile. DLT = doselimiting toxicity; RP2D = recommended phase 2 dose | Download Scientific Diagram
![Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials - Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials -](https://www.thelancet.com/cms/asset/d33452b0-96c9-44d0-99f3-3c96a91be908/gr1.jpg)
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials -
![Study Design. Abbreviations: BID, twice daily; HGOC, high‐grade ovarian... | Download Scientific Diagram Study Design. Abbreviations: BID, twice daily; HGOC, high‐grade ovarian... | Download Scientific Diagram](https://www.researchgate.net/publication/346496449/figure/fig1/AS:11431281179278355@1691172026748/Study-Design-Abbreviations-BID-twice-daily-HGOC-high-grade-ovarian-cancer-RP2D.png)
Study Design. Abbreviations: BID, twice daily; HGOC, high‐grade ovarian... | Download Scientific Diagram
![Optimal biological dose: a systematic review in cancer phase I clinical trials | BMC Cancer | Full Text Optimal biological dose: a systematic review in cancer phase I clinical trials | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-021-07782-z/MediaObjects/12885_2021_7782_Fig1_HTML.png)
Optimal biological dose: a systematic review in cancer phase I clinical trials | BMC Cancer | Full Text
![Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies | Journal of Clinical Oncology Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2014.58.1082/asset/images/zlj01915-5284-t03a.jpeg)
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies | Journal of Clinical Oncology
![Illustration of the chronic dose-limiting toxicity (DLT) concept. (*)... | Download Scientific Diagram Illustration of the chronic dose-limiting toxicity (DLT) concept. (*)... | Download Scientific Diagram](https://www.researchgate.net/publication/50891956/figure/fig2/AS:601789934096386@1520489309156/Illustration-of-the-chronic-dose-limiting-toxicity-DLT-concept-Coefficients.png)
Illustration of the chronic dose-limiting toxicity (DLT) concept. (*)... | Download Scientific Diagram
![Study design. BID twice daily, mCRPC metastatic castration-resistant... | Download Scientific Diagram Study design. BID twice daily, mCRPC metastatic castration-resistant... | Download Scientific Diagram](https://www.researchgate.net/publication/356370513/figure/fig1/AS:1136895203508224@1648068347648/Study-design-BID-twice-daily-mCRPC-metastatic-castration-resistant-prostate-cancer-MTD.png)
Study design. BID twice daily, mCRPC metastatic castration-resistant... | Download Scientific Diagram
![Assessing the reporting quality of early phase dose-finding trial protocols: a methodological review - eClinicalMedicine Assessing the reporting quality of early phase dose-finding trial protocols: a methodological review - eClinicalMedicine](https://www.thelancet.com/cms/attachment/268a9849-14ac-4bca-a3bc-8a01168f45ac/gr1_lrg.jpg)
Assessing the reporting quality of early phase dose-finding trial protocols: a methodological review - eClinicalMedicine
![A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer | Nature Communications A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-33267-z/MediaObjects/41467_2022_33267_Fig1_HTML.png)
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer | Nature Communications
![Example 2. A DDP segment: a phase I dose-finding study followed by a... | Download Scientific Diagram Example 2. A DDP segment: a phase I dose-finding study followed by a... | Download Scientific Diagram](https://www.researchgate.net/publication/371953085/figure/fig2/AS:11431281171261764@1688091232458/Example-2-A-DDP-segment-a-phase-I-dose-finding-study-followed-by-a-single-arm-phase-II.png)
Example 2. A DDP segment: a phase I dose-finding study followed by a... | Download Scientific Diagram
![Determination of Recommended Phase II Dose of Venetoclax (ABT-199) and Rituximab for Relapsed/Refractory CLL | Research To Practice Determination of Recommended Phase II Dose of Venetoclax (ABT-199) and Rituximab for Relapsed/Refractory CLL | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2015/3/7/Slide01.jpg)
Determination of Recommended Phase II Dose of Venetoclax (ABT-199) and Rituximab for Relapsed/Refractory CLL | Research To Practice
![Determination of Recommended Phase II Dose of Venetoclax (ABT-199) and Rituximab for Relapsed/Refractory CLL | Research To Practice Determination of Recommended Phase II Dose of Venetoclax (ABT-199) and Rituximab for Relapsed/Refractory CLL | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2015/3/7/Slide04.jpg)